SCHEMBL6780293

SCHEMBL6780293

COc1cc(C(=O)Nc2cc(N)ccc2C)cc(OC)c1OC

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.57
ABCB1 P08183 3/20 0.56
SMO Q99835 6/20 0.55
ABCC1 P33527 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
NPC1 O15118 1/20 0.53
USP2 O75604 1/20 0.53
TP53 P04637 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
HSD17B10 Q99714 1/20 0.53
HPGD P15428 1/20 0.53
ALDH1A1 P00352 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 1/20 0.52
LMNA P02545 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476328 0.86 PKM (0.59) MAPK14SMN1; SMN2HPGDALDH1A1MEN1
SCHEMBL28653236 0.80 ABCB1 (0.74) ABCB1SMN1; SMN2TP53ALDH1A1MEN1
SCHEMBL6485998 0.77 MAPT (0.77) SMN1; SMN2NPC1RAB9AHSD17B10HPGD
SCHEMBL10605968 0.76 GAA (0.66) SMN1; SMN2TP53HTTALDH1A1MEN1
SCHEMBL29960273 0.76 MAPT (0.57) MAPK14SMN1; SMN2TP53HTTHPGD
SCHEMBL5789916 0.76 MAPT (0.57) MAPK14SMN1; SMN2TP53HTTRAB9A
SCHEMBL11574114 0.75 PYGL (0.57) MAPK14SMN1; SMN2NPC1USP2HTT
SCHEMBL28863360 0.75 ALDH1A1 (0.62) SMN1; SMN2NPC1TP53HTTRAB9A
SCHEMBL10780310 0.75 HPGD (0.53) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL5646672 0.74 MAPT (0.56) SMN1; SMN2HTTRAB9AHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686467-B2 INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 ZENECA LIMITED (GB) 2004-02-03 US disclosed
US-20030166730-A1 Amide derivatives for the treatment of diseases mediated by cytokines ZENECA LIMITED 2003-09-04 US disclosed
US-6498274-B1 Amide derivatives for the treatment of diseases mediated by cytokines ZENECA LIMITED (GB) 2002-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166730-A1 Amide derivatives for the treatment of diseases mediated by cytokines IL2, IL6, IL6ST MAPK14 965/4885ABCB1 2272/4885SMO 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.